Oncosil Medical Ltd has released a press release.
CE Mark & Quarterly Activity Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from OncoSil Medical
- Second subject recruited at Monash Health Melbourne
- Appendix 4C and Quarterly update
- First OncoSil Device Implantation procedure completed
- Specialised Therapeutics Australia supporting OncoSil study
- US IRB Approval, MD Anderson Cancer Centre
Later from OncoSil Medical
- First UK subject recruited
- Appendix 4E - Preliminary Final Report 30 June 2017
- Progress update on Global Pancreatic Cancer Clinical Study
- R&D Refund
- Positive Early Study Results Presented at EANM Congress
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical